© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Rose is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an editor.
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
September 27, 2022
A recent review details strategies for mitigating the risks faced by pregnant patients with hemophilia or von Willebrand disease and their children.
September 26, 2022
The recommendations aim to make this type of evaluation more consistent in cases when children have suspicious bruising or bleeding patterns.
September 24, 2022
A small study suggests that comprehensive genomic profiling can help with clinical decision-making and predicting clinical outcomes in advanced biliary tract cancer, but further research is needed.
The rare condition can easily be confused with hepatocellular carcinoma, but immunohistochemical studies can help accurately diagnose intrahepatic sarcomatoid cholangiocarcinoma.
September 22, 2022
Morbidity and mortality remain high for patients with acquired hemophilia A, and advances in immunotherapy and hemostatic therapy are needed to improve outcomes.
September 17, 2022
The review discusses hydroxyurea and 3 additional drugs approved by the FDA—L-glutamine, crizanlizumab, and voxelotor—as well as agents currently being investigated to treat sickle cell disease (SCD).
The study pooled data from 4 clinical trials to gain insight into surgical outcomes in this complex population.
Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.
Sutimlimab demonstrated rapid efficacy in the study cohort, and platelet level improvements were sustained for the duration of treatment in nearly half of the participants.
The review highlights current strategies for myeloid cell targeting and novel agents targeting myeloid cells for cancer treatment.